Home Newsfeeds Raymond James Maintains Outperform on NGM Biopharmaceuticals, Raises Price Target to $6

Raymond James Maintains Outperform on NGM Biopharmaceuticals, Raises Price Target to $6

Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $4 to $6.

byBenzinga Newsdesk

November 4, 2022

1 minute read

Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $4 to $6.

News

BigCommerce Strengthens Privacy And Business Continuity Management With ISO 27701 And ISO 22301 Certifications

By Happy Mohamed

May 16, 8:20 AM

Latest certifications provide transparency into the company's security, privacy and compliance posture BigCommerce (NASDAQ:BIGC), a leading Open SaaS ecommerce platform for fast-growing and established B2C and

BIGC

TransDigm Group Analysts Boost Their Forecasts After Upbeat Results

By Avi Kapoor

May 8, 8:57 AM

TransDigm Group Incorporated (NYSE:TDG) reported better-than-expected results for its second quarter and raised FY24 outlook. TransDigm posted adjusted…

TDG

Watching MSCI Inc.; Spruce Point Capital Management Announces Investment Opinion Entitled “Indexing The Short Case Against MSCI”; Says The Co Could Face Up To 55%-65% Long-Term Downside Risk, Or $190.00–$244.00 Per Share

By Benzinga Newsdesk

January 17, 10:39 AM

NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital ManagementProvides Evidence That Each of MSCI's Four Business Segments is Under Pressure, Resulting in Client Retention

MSCI